Vivet Therapeutics is dedicated to developing innovative gene therapy treatments for orphan diseases. Vivet Therapeutics is focused on optimizing gene therapy through collaborating with the Fundacion para la Investigacion Medica Aplicada (CIMA, Universidad de Navarra) to develop new AAV vectors specifically targeting the liver and generating new technologies to optimize gene delivery and long term expression.
Vivet Therapeutics is a gene therapy biotech company with headquarters in Paris, France, dedicated to the research, development and future commercialization of gene therapy treatments for inherited liver disorders with high medical need.
The company's development strategy is to target the liver using a novel synthetic adeno associated virus (AAV-ANC80) to introduce therapeutic genes to hepatocytes, correcting the genetic disorder.
Vivet's keys to success are its exclusive license rights and access to know how granted by its strategic partners, FIMA and MEE, enabling it to address various inherited disorders such as Wilson's disease, Progressive Familiar Intrahepatic Cholestasis (PFIC) and Citrullinemia type I in close collaboration with the Center for Applied Medical Research (CIMA) in Pamplona, Spain.